Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.
FibroBiologics files a U.S. patent application for engineered cell technology designed to supply continuous GLP-1 therapy internally.
Find out all the key statistics for Fibrobiologics Inc (FBLG-Q), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
ORLANDO, FL / ACCESS Newswire / September 25, 2026 / RedChip Companies will air interviews with Nova Minerals Corp (NYSE American:NVA)(ASX:NVA) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 26, at 7:00 p.
Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.
Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.
The exclusive event will feature Pete O'Heeron, CEO, and Jason Davis, CFO, who will provide an overview of FibroBiologics' strategy to develop off-the-shelf fibroblast-based cell therapies for chronic diseases and regenerative medicine. The Company is advancing a platform designed to harness the regenerative and immune-modulating properties of fibroblasts across multiple indications, including chronic wound care, psoriasis, multiple sclerosis, degenerative disc disease, and thymus regeneration.
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,721,866, titled "Therapeutic Use of Fibroblasts for Use in Wound Healing." The patent, issued on September 1, 2026, covers
FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support an ongoing clinical trial for diabetic foot ulcers (DFUs). The compant describes the investigational treatment as a...
Tipranks Press Release.
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Leigh Steinberg to its Board of Directors. Widely regarded as the most influential sports agent of his generation, Mr. Steinberg brings five decades of dealmaking experience, a deep commitment
This is the newest page. Registered accounts read further back.